|
|Section2= |Section3= }} Beloranib is an experimental injectable〔(Zafgen Announces New Weight Loss and Safety Data from Phase 2 Trial of Beloranib in Hypothalamic Injury Associated Obesity at ENDO 2015 (2015) )〕 drug candidate for the treatment of obesity. It was discovered by CKD Pharmaceuticals and is currently being developed by Zafgen.〔(【引用サイトリンク】 News Release: Zafgen Secures $33 Million Series C Financing )〕 Beloranib, an analog of the natural chemical compound fumagillin, is an inhibitor of the enzyme METAP2. It was originally designed as angiogenesis inhibitor for the treatment of cancer. However, once the potential anti-obesity effects of METAP2 inhibition became apparent, the clinical development began to focus on these effects and beloranib has shown positive results in preliminary clinical trials for this indication.〔(【引用サイトリンク】 Fat-busting pill helps obese to shed two pounds a week - without changing their diets )〕 An ascending dose trial of 31 obese women was published in 2013, finding a dose that led to weight loss vs placebo. Zafgen is running a phase 3 trial for Prader–Willi syndrome and phase 2 trials for obesity. Results from the Phase II clinical trial for obesity mentioned earlier were promising with clinically meaningful weight loss and improvements in cardiometabolic risk factors in the treated group. ==References== 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Beloranib」の詳細全文を読む スポンサード リンク
|